UNSPSC 51172125: Drofenine or drofenine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C20H31NO2 and C20H31NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 4QWV355536 and MVB31OPW05, the base compound being chemically known as cyclohexaneacetic acid, .alpha.-phenyl-, 2- (diethylamino)ethyl ester but generally known as drofenine, which bears US NIH Compound Identifier 3166.

UNSPSC 51172125 Drofenine or drofenine hydrochloride is a Commodity code under which state and local governments procure pharmaceutical testing and pharmaceutical supply services. Recent state and local solicitations tagged with this code reflect two distinct procurement streams: drug-testing services for criminal justice and corrections departments, and generic pharmaceutical and over-the-counter product sourcing for multistate cooperative purchasing programs. The issuing bodies include county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances that serve state agencies and local government facilities. The scope of work encompasses specimen collection and confirmatory drug testing (immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid and hair testing) for offender supervision, as well as generic pharmaceutical procurement and distribution to participating public facilities through authorized wholesale channels.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, seeking offender specimen collection and drug testing services with proposals due July 23, 2026; the estimated contract value is $600,000 for two years commencing September 1, 2026, with three optional one-year renewals. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in late March 2026 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement to support state pharmacy benefit objectives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The mismatch between the code's nominal scope (drofenine hydrochloride, a specific pharmaceutical compound) and the actual procurements being tagged (broad drug-testing services and generic pharmaceutical sourcing) suggests limited direct relevance of this code to state and local procurement activity.